IL154183D0 - Cytotoxins, prodrugs, linkers and stabilizers useful therefor - Google Patents

Cytotoxins, prodrugs, linkers and stabilizers useful therefor

Info

Publication number
IL154183D0
IL154183D0 IL15418302A IL15418302A IL154183D0 IL 154183 D0 IL154183 D0 IL 154183D0 IL 15418302 A IL15418302 A IL 15418302A IL 15418302 A IL15418302 A IL 15418302A IL 154183 D0 IL154183 D0 IL 154183D0
Authority
IL
Israel
Prior art keywords
cytotoxins
linkers
prodrugs
useful therefor
stabilizers useful
Prior art date
Application number
IL15418302A
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29534201P priority Critical
Priority to US29519601P priority
Priority to US29525901P priority
Priority to US30490801P priority
Application filed by Medarex Inc filed Critical Medarex Inc
Priority to PCT/US2002/017210 priority patent/WO2002096910A1/en
Publication of IL154183D0 publication Critical patent/IL154183D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
IL15418302A 2001-05-31 2002-05-31 Cytotoxins, prodrugs, linkers and stabilizers useful therefor IL154183D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US29534201P true 2001-05-31 2001-05-31
US29519601P true 2001-05-31 2001-05-31
US29525901P true 2001-05-31 2001-05-31
US30490801P true 2001-07-11 2001-07-11
PCT/US2002/017210 WO2002096910A1 (en) 2001-05-31 2002-05-31 Cytotoxins, prodrugs, linkers and stabilizers useful therefor

Publications (1)

Publication Number Publication Date
IL154183D0 true IL154183D0 (en) 2003-07-31

Family

ID=27501653

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15418302A IL154183D0 (en) 2001-05-31 2002-05-31 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
IL154183A IL154183A (en) 2001-05-31 2003-01-29 Cytotoxic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154183A IL154183A (en) 2001-05-31 2003-01-29 Cytotoxic compounds

Country Status (11)

Country Link
US (8) US7129261B2 (en)
EP (2) EP1434778A4 (en)
JP (2) JP4961095B2 (en)
KR (1) KR20030033007A (en)
CN (2) CN1463270A (en)
AU (1) AU2002303929B9 (en)
CA (1) CA2448319C (en)
IL (2) IL154183D0 (en)
MX (1) MXPA03011094A (en)
NZ (1) NZ529788A (en)
WO (1) WO2002096910A1 (en)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1408960B1 (en) * 2001-02-22 2006-05-31 School Of Pharmacy, University Of London Benz-indole and benzo-quinoline derivatives as prodrugs for tumour treatment
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
IL154183D0 (en) * 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
JPWO2003106429A1 (en) * 2002-06-14 2005-10-13 武田薬品工業株式会社 Prodrugs and their preparation
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
DE60203491D1 (en) * 2002-08-02 2005-05-04 Inst Curie Paris Shiga toxin B-subunit as a vector for the diagnosis of tumors and for drug delivery to GB3 expressing tumors
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2004212641B2 (en) * 2003-02-19 2009-08-06 Natrix Separations Inc. Composite materials comprising supported porous gels
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JP4578470B2 (en) * 2003-04-22 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエIpsen Pharma S.A.S. Somatostatin vector
CA2536357A1 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US7335751B2 (en) * 2003-08-01 2008-02-26 Biocon Limited Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
CA2558859C (en) 2004-04-08 2014-02-04 Mcmaster University Membrane stacks
US20050239864A1 (en) * 2004-04-23 2005-10-27 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
RU2402548C2 (en) * 2004-05-19 2010-10-27 Медарекс, Инк. Chemical linkers and conjugates thereof
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
WO2005120701A1 (en) * 2004-06-07 2005-12-22 Mcmaster University Stable composite material comprising supported porous gels
RU2007103298A (en) * 2004-06-30 2008-08-10 Новартис АГ (CH) Compositions and methods for the delivery of antitumor agents
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
ES2386366T3 (en) * 2005-02-18 2012-08-17 Medarex, Inc. Human monoclonal antibody specific membrane antigen of the prostate (PSMA)
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BRPI0612845A8 (en) 2005-06-29 2018-01-23 Threshold Pharmaceuticals Inc compound, pharmaceutical composition, methods for treating cancer and for synthesizing a compound of formula alk-dispasador
AU2006268227A1 (en) 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
WO2007038658A2 (en) * 2005-09-26 2007-04-05 Medarex, Inc. Antibody-drug conjugates and methods of use
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
US7847105B2 (en) * 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006321841C1 (en) 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
CA2638902C (en) 2005-12-08 2014-09-23 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
ES2396569T3 (en) 2006-01-17 2013-02-22 Medarex, Inc. CD30 monoclonal antibodies lacking fucosyl and xylosyl residues
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
EP1994000B1 (en) * 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
SI2059536T1 (en) 2006-08-14 2014-06-30 Xencor, Inc. Optimized antibodies that target cd19
JP2010502220A (en) 2006-09-05 2010-01-28 ツィンマーマン デボラ エル. Antibodies and methods of use thereof for bone morphogenetic proteins and their receptors
KR101552735B1 (en) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. Human antibodies and their use to bind to CD 22
JP5517626B2 (en) 2006-12-13 2014-06-11 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Human antibodies and uses thereof to bind to Cd19
CA2672468A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2008083101A1 (en) 2006-12-26 2008-07-10 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2121667B1 (en) * 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemical linkers with single amino acids and conjugates thereof
JP5618549B2 (en) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Methods of treatment and related formulations used Egfr antibodies and src inhibitors
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN108424454A (en) 2007-08-14 2018-08-21 路德维格癌症研究所有限公司 Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
BRPI0816014A8 (en) 2007-10-01 2018-06-19 Squibb Bristol Myers Co monoclonal isolated human antibody, composition, conjugated antibody molecule partner isolated nucleic acid molecule, expression vector, host cell, method for preparing an anti-mesothelin antibody, the growth method of inhibiting a tumor cell expressing mesothelin, method treating cancer in an individual, anti-mesothelin antibody isolated, and methods of inhibiting the growth of a cell expressing mesothelin
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
NZ586514A (en) * 2007-11-30 2012-05-25 Squibb Bristol Myers Co Conjugates of anti-rg-1 antibodies for cancer treatment
US20110152252A1 (en) * 2007-12-18 2011-06-23 Institut Curie Shiga toxin b-subunit/chemotherapeutics conjugates
SI2235059T1 (en) 2007-12-26 2015-06-30 Xencor, Inc. Fc variants with altered binding to fcrn
US8246538B2 (en) * 2008-02-28 2012-08-21 K2M, Inc. Minimally invasive retractor with separable blades and methods of use
BRPI0912820A2 (en) 2008-05-20 2015-10-13 Neurogesx Inc prodrugs of acetaminophen relative hepatoprotective
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc human antibodies that bind to the gene 3 of lymphocyte activation (LAG-3) and uses these
KR20180083970A (en) * 2008-09-02 2018-07-23 나트릭스 세퍼레이션즈, 인코포레이티드 Chromatography membranes, devices containing them, and methods of use thereof
PL2344478T3 (en) * 2008-11-03 2018-02-28 Syntarga B.V. Cc-1065 analogs and their conjugates
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
HUE034196T2 (en) 2009-03-05 2018-02-28 Squibb & Sons Llc Fully human antibodies specific to cadm1
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
SG10201401604VA (en) 2009-04-20 2014-08-28 Oxford Biotherapeutics Ltd Antibodies Specific To Cadherin-17
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
KR20120093349A (en) * 2009-11-13 2012-08-22 나트릭스 세퍼레이션즈, 인코포레이티드 Hydrophobic interaction chromatography membranes, and methods of use thereof
SI2516468T1 (en) 2009-12-23 2016-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
CA2790434A1 (en) * 2010-02-18 2011-08-25 Anthony P. Shuber Compositions and methods for treating cancer
CN107253992A (en) 2010-05-27 2017-10-17 根马布股份公司 Monoclonal antibodies against her2
JP6177231B2 (en) 2011-04-20 2017-08-09 ゲンマブ エー/エス Her2 for the bispecific antibody
PT3056203T (en) * 2010-04-21 2018-02-15 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
CA2800769A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
CN106084053A (en) 2010-06-15 2016-11-09 根马布股份公司 Human Antibody Drug Conjugates Against Tissue Factor
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies having isoelectric points that have been modified
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
TWI564304B (en) 2010-12-30 2017-01-01 Takeda Pharmaceuticals Co Anti-cd38 antibodies
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012122059A1 (en) * 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
AU2012255721A1 (en) 2011-05-17 2014-01-09 Natrix Separations Inc. Layered tubular membranes for chromatography, and methods of use thereof
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP3228325A1 (en) 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2726094B1 (en) 2011-06-28 2016-12-14 Oxford BioTherapeutics Ltd Therapeutic and diagnostic target
UA114478C2 (en) 2011-06-28 2017-06-26 Берлін-Хемі Аг Antibodies to adp-ribosyl cyclase 2
JP6243330B2 (en) 2011-07-06 2017-12-06 ゲンマブ ビー.ブイ. Antibody variants and their use
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab B V Dimeric protein with triple mutations
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013036753A1 (en) * 2011-09-07 2013-03-14 The Scripps Research Institute Chiral compounds of varying conformational rigidity and methods of synthesis
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
EP2592103A1 (en) 2011-11-08 2013-05-15 Adriacell S.p.A. Polymer aldehyde derivatives
AU2013221873B2 (en) 2012-02-13 2016-11-17 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
CN104220442B (en) * 2012-04-05 2016-11-23 内尔维阿诺医学科学有限公司 Alkylating agents
WO2013160340A1 (en) * 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimization of antibodies which bind to lymphocyte activation gene 3 (LAG-3) and their uses
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US20150210758A1 (en) 2012-08-14 2015-07-30 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
US20140161790A1 (en) 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2014108198A1 (en) 2013-01-10 2014-07-17 Genmab B.V. Human igg1 fc region variants and uses thereof
KR20150129685A (en) 2013-03-15 2015-11-20 젠코어 인코포레이티드 Heterodimeric proteins
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN103933575B (en) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 A three-tooth connection and its application
ES2628156T3 (en) 2013-02-14 2017-08-01 Bristol-Myers Squibb Company Tubulisina compounds, methods for their manufacture and use
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2015044003A1 (en) * 2013-09-25 2015-04-02 Nerviano Medical Sciences S.R.L. THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
PE05612016A1 (en) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
MX2016004659A (en) 2013-10-11 2017-08-02 Asana Biosciences Llc Protein-polymer-drug conjugates.
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
MX2016009070A (en) * 2014-01-10 2016-09-09 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity.
CN105899237A (en) 2014-01-10 2016-08-24 斯索恩生物制药有限公司 Duocarmycin adcs for use in treatment of endometrial cancer
AU2015205574A1 (en) 2014-01-10 2016-07-07 Synthon Biopharmaceuticals B.V. Method for purifying Cys-linked antibody-drug conjugates
BR112016020492A2 (en) 2014-03-20 2017-10-10 Squibb Bristol Myers Co Fibronectin molecules stabilized based on the structures
CA2943621A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
CA2951234A1 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN107074948A (en) 2014-07-11 2017-08-18 根马布股份公司 Antibodies binding AXL
US20180326084A1 (en) 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
TW201625693A (en) 2014-11-21 2016-07-16 Squibb Bristol Myers Co Antibodies against CD73 and uses thereof
JP2017536829A (en) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドXencor、 Inc. Heterodimeric antibody that binds to Cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TW201632532A (en) 2015-01-14 2016-09-16 Squibb Bristol Myers Co Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
CN106279352A (en) 2015-05-29 2017-01-04 上海新理念生物医药科技有限公司 Derivatives of dolastatin 10 and application thereof
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US20170119902A1 (en) 2015-11-03 2017-05-04 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN106729743A (en) 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 Anti-ErbB2 antibody-drug conjugate, composition, preparation method and application of anti-ErbB2 antibody-drug conjugate
CN108699136A (en) 2015-12-07 2018-10-23 Xencor股份有限公司 Heterodimeric antibodies that bind cd3 and psma
CN109476740A (en) 2016-03-04 2019-03-15 百时美施贵宝公司 Utilize the combination therapy of anti-CD73 antibody
CA3026880A1 (en) 2016-06-08 2017-12-14 Paul Foster Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
SG11201900026TA (en) 2016-07-14 2019-01-30 Squibb Bristol Myers Co Antibodies against tim3 and uses thereof
CN109641911A (en) 2016-08-19 2019-04-16 百时美施贵宝公司 Seco- cyclopropyl pyrrolo-indole compound and its antibody-drug conjugates and preparation and application
US20180110873A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
KR20190070977A (en) 2016-11-01 2019-06-21 젠맵 비. 브이 Polypeptide variants and uses thereof
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018218056A1 (en) 2017-05-25 2018-11-29 Birstol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US20190055245A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Toll-like receptor 7 (tlr7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US20190055243A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Toll-like receptor 7 (tlr7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US20190055247A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Toll-like receptor 7 (tlr7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US20190055244A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Toll-like receptor 7 (tlr7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US20190055246A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Toll-like receptor 7 (tlr7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US20190144549A1 (en) 2017-10-10 2019-05-16 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas blanghard
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978757A (en) 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
CA1238907A (en) 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4912227A (en) 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0271581B1 (en) 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
DE3750612D1 (en) * 1986-12-19 1994-11-03 Upjohn Co Cc-1065 analog.
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
JPS6428264A (en) * 1987-07-21 1989-01-30 Sumitomo Electric Industries Production of superconducting material
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US4994578A (en) * 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5147786A (en) 1988-04-22 1992-09-15 Monsanto Company Immunoassay for the detection of α-haloacetamides
JP2642165B2 (en) * 1988-07-22 1997-08-20 協和醗酵工業株式会社 New dc-89 compounds and their preparation
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US4915278A (en) * 1988-11-03 1990-04-10 Smith Kenneth W Portable container
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
JP2598116B2 (en) 1988-12-28 1997-04-09 協和醗酵工業株式会社 New substances dc113
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3907562A1 (en) 1989-03-09 1990-09-13 Bayer Ag Antisense oligonucleotides for the inhibition of transaktivatorzielsequenz (tar) and the synthesis of the transactivator (tat) of the HIV-1 and the use thereof
US5075181A (en) * 1989-05-05 1991-12-24 Kennametal Inc. High hardness/high compressive stress multilayer coated tool
EP0471796A4 (en) 1989-05-10 1993-05-05 Sloan Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
WO1990015065A1 (en) 1989-06-05 1990-12-13 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides and methods for preparing the same
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (en) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Dc-88a derivatives
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
CA2071510C (en) 1989-10-24 2004-07-06 Chris A. Buhr 2' modified oligonucleotides
US5495009A (en) * 1989-10-24 1996-02-27 Gilead Sciences, Inc. Oligonucleotide analogs containing thioformacetal linkages
AU653504B2 (en) 1989-10-24 1994-10-06 Isis Pharmaceuticals, Inc. Oligonucleotide analogs with novel linkages
US5334528A (en) 1989-10-30 1994-08-02 The Regents Of The University Of California Monoclonal antibodies to cyclodiene insecticides and method for detecting the same
US5180819A (en) 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566D1 (en) 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991011535A1 (en) 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
KR100208957B1 (en) 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 Novel cc-1065 analogues
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5137877B1 (en) * 1990-05-14 1996-01-30 Squibb Bristol Myers Co Bifunctional linking compounds conjugates and methods for their production
DK0786469T3 (en) 1990-06-11 2006-07-10 Gilead Sciences Inc Nucleic acid
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69121334T2 (en) * 1990-07-26 1997-03-20 Kyowa Hakko Kogyo Kk DC-89 derivatives as antitumor agents
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06505704A (en) 1990-09-20 1994-06-30
JPH06503715A (en) 1990-09-21 1994-04-28
JPH04154298A (en) * 1990-10-17 1992-05-27 Pioneer Electron Corp Speaker
AU9094991A (en) 1990-11-23 1992-06-25 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
WO1992010590A1 (en) 1990-12-10 1992-06-25 Gilead Sciences, Inc. Inhibition of transcription by formation of triple helixes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
DE69233745D1 (en) 1991-12-02 2008-10-23 Cambridge Antibody Tech Production of autoantibodies on phage surfaces starting from antibody segment libraries
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
JPH0597853A (en) 1991-10-07 1993-04-20 Kyowa Hakko Kogyo Co Ltd Hydrobromic acid salt of dc-89 derivative
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DK0563475T3 (en) 1992-03-25 2000-09-18 Immunogen Inc Conjugates of cell binding agents and derivatives of CC-1065
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JP3514490B2 (en) * 1992-08-21 2004-03-31 杏林製薬株式会社 Trifluoromethyl pyrrolo indole carboxylic acid ester derivatives and a method for manufacturing the same
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
DE4314091A1 (en) 1993-04-29 1994-11-03 Boehringer Mannheim Gmbh Immunological detection method for triazines
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5773011A (en) 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5786377A (en) 1993-11-19 1998-07-28 Universidad De Santiago De Compostela Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications
DE4410559A1 (en) * 1994-03-26 1995-09-28 Hoechst Ag Oriented polyolefin with an amorphous polymer, a process for their preparation and their use
PT705833E (en) * 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derived from dc-89
JPH07309761A (en) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd Method for stabilizing duocamycin derivative
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
NZ291368A (en) 1994-08-19 1999-04-29 Wallone Region A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices
CA2201097A1 (en) 1994-09-30 1996-04-11 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agents
US5580089A (en) * 1994-10-11 1996-12-03 Kolka; David B. Vehicle stabilization system and method
AU693283B2 (en) * 1994-11-29 1998-06-25 Kyorin Pharmaceutical Co. Ltd. Acrylamide derivatives and process for producing the same
US5769650A (en) * 1995-06-19 1998-06-23 Sumitomo Wiring Systems, Ltd. Connector and cover therefor
US5846645A (en) * 1995-03-03 1998-12-08 Asahi Glass Company Ltd. Fluorocarbon resin-coated product
WO1996035451A1 (en) 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Novel toxin complex
US5686237A (en) 1995-06-05 1997-11-11 Al-Bayati; Mohammed A. S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5646298A (en) * 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5545805A (en) * 1995-06-07 1996-08-13 Chesner Engineering, Pc Enhanced stabilization of lead in solid residues using acid oxyanion and alkali-metal carbonate treatment
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP0862553A4 (en) 1995-10-03 1999-02-03 Scripps Research Inst Cbi analogs of cc-1065 and the duocarmycins
DE69632989D1 (en) * 1995-10-17 2004-09-02 Combichem Inc Template for the synthesis of combinatorial libraries in solution
JP2000503639A (en) * 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー Linker such branched hydrazone
US5760072A (en) * 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
US5685237A (en) * 1996-01-16 1997-11-11 David Lehrman Extendable support foot for an ironing board
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
WO1997032850A1 (en) 1996-03-08 1997-09-12 The Scripps Research Institute Mcbi analogs of cc-1065 and the duocarmycins
US5843937A (en) * 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
AU3217897A (en) 1996-05-31 1998-01-05 Scripps Research Institute, The Analogs of cc-1065 and the duocarmycins
WO1998009966A1 (en) * 1996-09-03 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JPH1087666A (en) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd Intermediate for producing duocarmycin sa and its derivative and production thereof
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1998025900A1 (en) 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Compounds having antitumor activity
WO1998043663A1 (en) 1997-03-28 1998-10-08 The Scripps Research Institute Sandramycin analogs
AU7274898A (en) 1997-05-07 1998-11-27 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
WO1998052925A1 (en) 1997-05-22 1998-11-26 The Scripps Research Institute Analogs of duocarmycin and cc-1065
US6316522B1 (en) 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6262271B1 (en) * 1997-10-14 2001-07-17 The Scripps Research Institute ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins
AU1807999A (en) 1997-12-08 1999-06-28 Scripps Research Institute, The Synthesis of cc-1065/duocarmycin analogs
JP3045706B1 (en) 1998-09-14 2000-05-29 科学技術振興事業団 Compounds and their synthesis alkylating specific nucleotide sequence of the Dna
EP1144011B1 (en) 1998-12-11 2010-03-10 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1210433A2 (en) 1999-08-31 2002-06-05 Board Of Regents The University Of Texas System Methods and compositions of a novel serine protease inhibitor
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
DE10008089A1 (en) 2000-02-22 2001-10-31 Biotechnolog Forschung Gmbh Production of tubulysin compounds comprises multi-stage process including condensation of N-methylpipecolinoyl-isoleucine with substituted thiazole-4-carboxylic acid derivative
US6555693B2 (en) 2000-03-16 2003-04-29 Genesoft, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
WO2001083482A1 (en) 2000-05-03 2001-11-08 The Scripps Research Institute Dna alkylating agent and activation thereof
JP4061819B2 (en) 2000-05-12 2008-03-19 独立行政法人科学技術振興機構 Synthesis method of the inter-strand cross-linking agent
US7214663B2 (en) * 2000-06-14 2007-05-08 Medarex, Inc. Tripeptide prodrug compounds
JP2004510703A (en) 2000-06-14 2004-04-08 メダレックス,インコーポレイティド Enzyme - degradable prodrug compound
WO2001095943A2 (en) 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
US7402556B2 (en) 2000-08-24 2008-07-22 Medarex, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
EP1243276A1 (en) 2001-03-23 2002-09-25 Patrick Henry Beusker Elongated and multiple spacers containing activatible prodrugs
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
IL154183D0 (en) 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
MXPA03010961A (en) * 2001-05-31 2004-02-27 Vertex Pharma Thiazole compounds useful as inhibitors of protein kinases.
US6897034B2 (en) * 2001-06-11 2005-05-24 Medarex, Inc. CD10-activated prodrug compounds
CA2459308A1 (en) 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
TW557623B (en) * 2001-11-28 2003-10-11 Ind Tech Res Inst Integrated demodulator for single-phase input frequency modulation signal
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
AU2003266233A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel tubulysin analogues
WO2004005326A2 (en) 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysin conjugates
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
DE602004027888D1 (en) 2003-02-20 2010-08-12 Seattle Genetics Inc Anti-CD70 antibody-drug conjugates and their
US20050026987A1 (en) * 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US7180819B1 (en) 2005-10-04 2007-02-20 Lsi Logic Corporation Converting dual port memory into 2 single port memories
EP1994000B1 (en) 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates

Also Published As

Publication number Publication date
US20030073852A1 (en) 2003-04-17
MXPA03011094A (en) 2004-12-06
EP1434778A4 (en) 2005-07-13
CN101671335A (en) 2010-03-17
IL154183A (en) 2012-07-31
US7087600B2 (en) 2006-08-08
KR20030033007A (en) 2003-04-26
CA2448319A1 (en) 2002-12-05
JP2005500273A (en) 2005-01-06
US20060013860A1 (en) 2006-01-19
EP2266986A1 (en) 2010-12-29
US20090209734A1 (en) 2009-08-20
US6989452B2 (en) 2006-01-24
CA2448319C (en) 2010-07-27
JP2009155342A (en) 2009-07-16
WO2002096910A1 (en) 2002-12-05
AU2002303929B9 (en) 2007-01-25
US7507420B2 (en) 2009-03-24
US20030050331A1 (en) 2003-03-13
NZ529788A (en) 2003-12-19
US20090175888A1 (en) 2009-07-09
US7498302B2 (en) 2009-03-03
AU2002303929A1 (en) 2002-12-09
JP4961095B2 (en) 2012-06-27
US20050272798A1 (en) 2005-12-08
US7129261B2 (en) 2006-10-31
CN1463270A (en) 2003-12-24
US7977465B2 (en) 2011-07-12
USRE41252E1 (en) 2010-04-20
EP1434778A1 (en) 2004-07-07
US20030064984A1 (en) 2003-04-03
AU2002303929B2 (en) 2006-12-21
US8034959B2 (en) 2011-10-11

Similar Documents

Publication Publication Date Title
DE60230896D1 (en) Mikronadeltransportvorrichtung
DE60234189D1 (en) Selbst-formbare annuloplastie-ringprothese
DE60224810D1 (en) Radiotherapie-gerät
DE60235233D1 (en) Dicom-xml-generator
GB2389452B (en) Ion-guide
DE60229114D1 (en) Cathepsincystein-proteasehemmer
DE60235907D1 (en) Flächiges implantat
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
DE50213124D1 (en) Button-balloon-system
DE60216490D1 (en) Mehrfunktionelle thioxanthon-photoinitiatoren
DE60238039D1 (en) Polyurethanhartschaumstoffe
GB2359206B (en) Amplifier arrangement
GB2383263B (en) Bed
DE60221642D1 (en) O-desmethyl-venlafaxine succinat salz
DE60112974D1 (en) Carbolinderivate
DE60228954D1 (en) Pyruvatderivate
DE60214551D1 (en) Modulares airbagaufblassystem
HK1070375A1 (en) Tetrafluoroethylene-perfluorobutylethene-copolymer
ZA200206810B (en) Modified factor VIII.
AU5211501A (en) Headset
MXPA03005406A (en) Erythropoietin conjugates.
DE50206308D1 (en) Thermographieverfahren
MXPA03004975A (en) Thioether substituted imidazoquinolines.
HK1058453A1 (en) Speaker
HK1066170A1 (en) 6-substitued pyrido-pyrimidines